From Phage Surface to Bedside: Development of Therapeutic Monoclonal Antibodies using Phage Display

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Current Pharmacology Reports

• Publication date

  2025-11-11

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s40495-025-00435-w
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning

  2025cited by this paper
• Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics

  2025cited by this paper
• Monoclonal antibodies for diagnosis of viral diseases: a comprehensive review

  2025cited by this paper
• A diverse semisynthetic humanized scFv phage display library for anti-CXCL16 antibodies

  2025cited by this paper
• Pioneer: a synthetic human antibody phage display library for rapid therapeutic lead generation

  2025cited by this paper
• Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases

  2024cited by this paper
• Phage display technology and its impact in the discovery of novel protein-based drugs

  2024cited by this paper
• A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach

  2024cited by this paper
• A new era of antibody discovery: an in-depth review of AI-driven approaches.

  2024cited by this paper
• Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (scFv) Antibody Selection against Claudin 18.2 via Phage Display

  2024cited by this paper
• Deep mining of antibody phage-display selections using Oxford Nanopore Technologies and Dual Unique Molecular Identifiers.

  2024cited by this paper
• Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

  2024cited by this paper
• Antibodies to watch in 2024

  2024cited by this paper
• Developing Recombinant Antibodies by Phage Display Technology to Neutralize Viral Infectious Diseases.

  2024cited by this paper
• The Application of Machine Learning on Antibody Discovery and Optimization

  2024cited by this paper
• Monoclonal antibodies: From magic bullet to precision weapon

  2024cited by this paper
• A Comprehensive Review on Phage Therapy and Phage-Based Drug Development

  2024cited by this paper
• Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges

  2024cited by this paper
• The pComb3 Phagemid Family of Phage Display Vectors.

  2023cited by this paper
• Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry

  2023cited by this paper
• Insights into next generation sequencing guided antibody selection strategies

  2023cited by this paper
• Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

  2023cited by this paper
• An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries

  2023cited by this paper
• Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens

  2023cited by this paper
• Evolution of phage display libraries for therapeutic antibody discovery

  2023influential reference
• Highly reliable GIGA-sized synthetic human therapeutic antibody library construction

  2023cited by this paper
• Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies

  2023cited by this paper
• Discovery and optimization of a broadly-neutralizing human monoclonal antibody against long-chain α-neurotoxins from snakes

  2023cited by this paper
• The RESP AI model accelerates the identification of tight-binding antibodies

  2023cited by this paper
• Bioengineering of Antibody Fragments: Challenges and Opportunities

  2023cited by this paper
• Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning

  2023cited by this paper
• Computational and artificial intelligence-based methods for antibody development.

  2023cited by this paper
• Antibody variable region engineering for improving cancer immunotherapy

  2022cited by this paper
• A Novel Synthetic Antibody Library with Complementarity-Determining Region Diversities Designed for an Improved Amplification Profile

  2022cited by this paper
• Advances in antibody phage display technology.

  2022influential reference
• A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies

  2022cited by this paper
• A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration

  2022cited by this paper
• Leveraging monoclonal antibodies as therapeutics to address antimicrobial resistance in bacteria

  2022cited by this paper
• Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology

  2022cited by this paper
• Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics

  2022cited by this paper
• Hybridoma technology; advancements, clinical significance, and future aspects

  2021cited by this paper
• Tralokinumab: First Approval

  2021cited by this paper
• Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery.

  2021cited by this paper
• A single donor is sufficient to produce a highly functional in vitro antibody library

  2021cited by this paper
• Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

  2021cited by this paper
• Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength

  2021cited by this paper
• Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries

  2021cited by this paper
• Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization

  2021cited by this paper
• Single B cell technologies for monoclonal antibody discovery.

  2021cited by this paper
• Phage display and other peptide display technologies.

  2021cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• Human antibodies neutralizing diphtheria toxin in vitro and in vivo

  2020cited by this paper
• Recent advances in CHO cell line development for recombinant protein production.

  2020cited by this paper
• Development of therapeutic antibodies for the treatment of diseases

  2020cited by this paper
• Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

  2020cited by this paper
• Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

  2020influential reference
• Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR

  2020cited by this paper
• Construction of Antibody Phage Libraries and Their Application in Veterinary Immunovirology

  2020cited by this paper
• Development of an antibody cocktail for treatment of Sudan virus infection

  2020influential reference
• High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System

  2020influential reference
• Phage Display in the Quest for New Selective Recognition Elements for Biosensors

  2019cited by this paper
• Emapalumab: First Global Approval

  2019cited by this paper
• ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery

  2019cited by this paper
• Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues

  2019cited by this paper
• David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments

  2019cited by this paper
• Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies.

  2019cited by this paper
• Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation

  2019cited by this paper
• Advances in the Production and Batch Reformatting of Phage Antibody Libraries

  2019cited by this paper
• Phage Display Libraries for Antibody Therapeutic Discovery and Development

  2019influential reference
• A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli

  2019cited by this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cited by this paper
• Moxetumomab Pasudotox: First Global Approval

  2018cited by this paper
• Use of Surface Plasmon Resonance (SPR) to Determine Binding Affinities and Kinetic Parameters Between Components Important in Fusion Machinery.

  2018cited by this paper
• Lanadelumab: First Global Approval

  2018cited by this paper
• Basics of Antibody Phage Display Technology

  2018cited by this paper
• Avelumab: A Review in Metastatic Merkel Cell Carcinoma

  2018cited by this paper
• Naïve Human Antibody Libraries for Infectious Diseases

  2018influential reference
• Design and Conduct Considerations for First‐in‐Human Trials

  2018cited by this paper
• Immune TB Antibody Phage Display Library as a Tool To Study B Cell Immunity in TB Infections

  2018cited by this paper
• Generation, Diversity Determination, and Application to Antibody Selection of a Human Naïve Fab Library

  2017cited by this paper
• Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

  2017cited by this paper
• Guselkumab: First Global Approval

  2017cited by this paper
• Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness

  2017cited by this paper
• Antibody-Based Protective Immunity against Helminth Infections: Antibody Phage Display Derived Antibodies against BmR1 Antigen

  2017cited by this paper
• Laboratory Scale Production and Purification of a Therapeutic Antibody.

  2017cited by this paper
• Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning

  2017cited by this paper
• Generation of a naïve human single chain variable fragment (scFv) library for the identification of monoclonal scFv against Salmonella Typhi Hemolysin E antigen.

  2016cited by this paper
• Design and construction of a new human naïve single-chain fragment variable antibody library, IORISS1.

  2016cited by this paper
• Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody

  2016cited by this paper
• Atezolizumab: First Global Approval

  2016cited by this paper
• Necitumumab: First Global Approval

  2016cited by this paper
• Ixekizumab: First Global Approval

  2016cited by this paper
• Understanding differences between synthetic and natural antibodies can help improve antibody engineering

  2016cited by this paper
• Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic

  2016cited by this paper
• Phage display-derived human antibodies in clinical development and therapy

  2016influential reference
• Assessment of antibody library diversity through next generation sequencing and technical error compensation

  2016cited by this paper
• Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library

  2016cited by this paper
• Generation and analysis of the improved human HAL9/10 antibody phage display libraries

  2015cited by this paper
• Mammalian Cell Culture Process for Monoclonal Antibody Production: Nonlinear Modelling and Parameter Estimation

  2015cited by this paper
• Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”

  2015cited by this paper

• No citing papers are available for this paper.